Back to Journals » OncoTargets and Therapy » Volume 11

Primary effusion lymphoma: current perspectives

Authors Narkhede M, Arora S, Ujjani C

Received 6 March 2018

Accepted for publication 19 April 2018

Published 28 June 2018 Volume 2018:11 Pages 3747—3754


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Tohru Yamada

Mayur Narkhede,1 Shagun Arora,2 Chaitra Ujjani1

1Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA; 2Division of Hematology and Oncology, University of California, San Francisco, CA, USA

Primary effusion lymphoma (PEL) is a rare and aggressive disease, affecting a unique population of patients who are often elderly or immunocompromised. PEL is associated with human herpesvirus type-8 infection and most commonly presents as malignant effusions of the body cavities. Patients diagnosed with PEL often have a compromised immune system from secondary conditions such as HIV. Chemotherapy has traditionally been the cornerstone of treatment for patients with a good performance status and no significant comorbidities. However, an optimal regimen does not exist. Most patients with PEL experience a relapse after frontline therapy within 6–8 months and subsequently require further treatment. In recent years, our understanding of the molecular drivers and environmental factors affecting the pathogenesis of PEL has expanded. This review will discuss the pathogenesis of PEL and various management approaches available in the frontline and relapsed setting as well as targeted agents that have shown promise in this disease.

Keywords: HIV-associated lymphomas, primary effusion lymphoma, HHV8-associated lymphomas

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]